UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-41440

Virax Biolabs Group Limited
(Registrant's Name)

BioCity Glasgow
Bo'Ness Road Newhouse
Lanarkshire, ML1 SUH
United Kingdom
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

When used in this Form 6-K, unless otherwise indicated, the terms "**the Company**," "**Virax**," "**we**," "**us**" and "**our**" refer to Virax Biolabs Group Limited. and its subsidiaries.

Information Contained in this Form 6-K Report

On November 24, 2026, Virax Biolabs Group Limited issued a press release today announcing that through its wholly owned subsidiary, Virax Biolabs (UK) Limited, has signed a supplemental agreement, at Fosun Diagnostics' request, extending the parties' commercial supply framework for ImmuneSelect research-use immune profiling products to India. The expanded territory covers seven markets: India, Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia.

KEY HIGHLIGHTS:

- Signed supplemental agreement adds India to a commercial supply framework spanning seven markets.
- Customer sampling underway in Thailand, Singapore and the Philippines.
- Indian customer enquiry received for ImmuneSelect peptide pools.
- Preliminary discussions with Fosun cover potential ImmuneSelect distribution in mainland China and local manufacturing at a Fosun facility.

A copy of the press release dated November 24, 2026 is included as Exhibit 99.1 to this report.

Exhibits

Exhibit No	Description

99.1	Press release dated November 24, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIRAX BIOLABS GROUP LIMITED

Date: November 24, 2026

By: /s/ James Foster
James Foster, Chief Executive Officer

Exhibit 99.1

Virax Biolabs Expands Fosun Diagnostics Supply Agreement to India as ImmuneSelect Evaluations Advance Across Asia

Fosun-requested expansion adds a seventh market; customer sampling underway in Thailand, Singapore and the Philippines

LONDON, November 24, 2026 /PRNewswire/ - Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has signed a supplemental agreement, at Fosun Diagnostics' request, extending the parties' commercial supply framework for ImmuneSelect research-use immune profiling products to India. The expanded territory covers seven markets: India, Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia.

KEY HIGHLIGHTS:

- Signed supplemental agreement adds India to a commercial supply framework spanning seven markets.
- Customer sampling underway in Thailand, Singapore and the Philippines.
- Indian customer enquiry received for ImmuneSelect peptide pools.
- Preliminary discussions with Fosun cover potential ImmuneSelect distribution in mainland China and local manufacturing at a Fosun facility.

ImmuneSelect is Virax's commercially available research-use-only ("RUO") immune profiling product line and is distinct from ViraxImmune™, the Company's in-development diagnostic platform currently progressing through clinical and regulatory development.

Fosun Diagnostics is the core diagnostics business under Fosun Medtech, a division of Fosun Pharma (600196.SH; 02196.HK). Fosun Pharma reported 2025 revenue of RMB41.662 billion, approximately US$5.8 billion. Virax believes Fosun Diagnostics provides an established commercial partner for expanding ImmuneSelect's reach.

The expansion builds on the supply agreement announced on July 9, 2026, and earlier Indian interest identified by Fosun. The wider Fosun Pharma group has an established presence in India through its Hyderabad-based subsidiary Gland Pharma and local group offices. Virax is also referring an Indian enquiry for ImmuneSelect peptide pools to Fosun, with any resulting purchase orders to be placed by Fosun with Virax under the expanded supply framework.

According to the India BioEconomy Report 2026, India's wider bioeconomy was estimated at US$195.3 billion in 2025, up 18% year on year, with 11,855 biotechnology startups.

Virax and Fosun are also discussing potential distribution of ImmuneSelect products in mainland China and local manufacturing at a Fosun facility to support domestic and regional supply. Both opportunities remain preliminary, fall outside the current supply agreement and are subject to technical evaluation, negotiation, and execution of definitive agreements. No definitive agreement has been signed for either opportunity. There can be no assurance that either opportunity will result in a definitive agreement, product supply or revenue.

"Fosun's request to add India and customer sampling across Southeast Asia demonstrate the growing scope of our relationship," said James Foster, Chairman and Chief Executive Officer of Virax Biolabs. "Potential China arrangements with Fosun would build on our existing mainland distribution network. Our priority is converting these opportunities into recurring ImmuneSelect sales."

"We requested India's addition following customer interest in ImmuneSelect," said Leon Zhang, International Commercial Head for China Domestic Business, Fosun MedTech. "We are supporting evaluations across Southeast Asia, and the expanded agreement gives us an opportunity to introduce ImmuneSelect to research customers in India."

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune™, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.

For more information, please visit www.viraxbiolabs.com.

About Fosun Diagnostics

Founded in 1989, Fosun Diagnostics is an in vitro diagnostics company focused on the development and implementation of innovative diagnostic technologies and products. Fosun Diagnostics is the core entity of the diagnostics business under Fosun Medtech, a division of Fosun Pharma, with six major R&D and production bases across China. Fosun Pharma is an innovation-driven global pharmaceutical and healthcare group listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, with businesses across pharmaceuticals, medical technologies, diagnostics and healthcare services.
For more information, please visit www.fosundiagnostics.com.

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities, including the anticipated benefits of the expanded Fosun Diagnostics agreement, potential China distribution and manufacturing arrangements, potential orders and repeat reagent sales. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.

In evaluating these forward-looking statements, you should consider various factors, including: our ability to keep pace with new technology and changing market needs; the possibility that the supply agreement with Fosun Diagnostics, including the India supplemental agreement, may not generate anticipated revenue or achieve expected commercial results; the possibility that customer enquiries, sampling and evaluations may not convert into purchase orders or repeat sales; the possibility that China distribution and manufacturing discussions may not lead to definitive agreements or commercial activity; our ability to meet customer product and performance requirements; dependence on commercial partners; regulatory, import, logistics and supply-chain requirements; potential for clinical, analytical or performance studies to generate statistically and/or clinically meaningful evidence of efficacy and/or safety sufficient to support regulatory submissions, commercialization or adoption, failure of preliminary, interim or top-line data to accurately reflect the complete results of a trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to secure FDA and other regulators’ agreement on the regulatory path for ViraxImmune™ or other potential products; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.

These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

These and other important factors are described in detail in the “Risk Factors” section of Virax’s Annual Report on Form 20-F for the year ended March 31, 2026. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Company Contact:

Virax Biolabs Group Limited
Phone: +44 020 7788 7414
Email: info@viraxbiolabs.com